Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP206
- Development stage
- Phase 1
- Lead developer
- Leadiant Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
STP206 is an investigational, orally administered live biotherapeutic product comprising *Lactobacillus acidophilus* and *Bifidobacterium animalis* subsp. *lactis*. It was developed by Sigma-Tau Pharmaceuticals, subsequently renamed Leadiant Biosciences, as a pharmaceutical-grade microbiome therapy intended to reduce the risk of necrotizing enterocolitis in very-low-birth-weight and extremely-low-birth-weight premature infants. The product received FDA orphan-drug designation for prevention of necrotizing enterocolitis and was evaluated in completed Phase 1 studies in healthy adults and premature neonates. ([firstwordpharma.com](https://firstwordpharma.com/story/2533395))
- Other names
- STP-206STP206STP 206
Beyond the preview
Go deeper on STP206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP206.